Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 4/20 | 0.47 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | BRD2 | P25440 | 1/20 | 0.38 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CD38 | P28907 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22003815 | 0.84 | ACLY (0.51) | ACLYBRD4MAPTCD38RXFP1 | |
| SCHEMBL22004293 | 0.82 | ACLY (0.50) | ACLYBRD4THRBMAPTCD38 | |
| SCHEMBL22004317 | 0.81 | ACLY (0.50) | ACLYBRD4CD38TP53KDR | |
| SCHEMBL22004122 | 0.77 | ACLY (0.46) | ACLYTHRBMAPTHTR2AHTR2C | |
| SCHEMBL22004395 | 0.75 | KCNH2 (0.45) | ACLYTHRBMAPTTDP1HTR2A | |
| SCHEMBL22005108 | 0.74 | ACLY (0.50) | ACLYTHRBMAPTKDR | |
| SCHEMBL22003806 | 0.74 | HTT (0.50) | ACLY | |
| SCHEMBL22004327 | 0.74 | ACLY (0.52) | ACLYTHRBMAPTHTR2AHTR2C | |
| SCHEMBL22004313 | 0.73 | ACLY (0.47) | ACLYTHRBMAPTHTR2AHTR2C | |
| SCHEMBL22003798 | 0.72 | ACLY (0.44) | ACLYTHRBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020102616-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | ACLY 1/4885BRD4 3711/4885BRD2 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.